[Federal Register Volume 68, Number 155 (Tuesday, August 12, 2003)]
[Notices]
[Page 47930]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-20492]


=======================================================================
-----------------------------------------------------------------------

UNITED STATES INTERNATIONAL TRADE COMMISSION

[Inv. No. 337-TA-479]


In the Matter of: Certain Coamoxiclav Products, Potassium 
Clavulanate Products, and Other Products Derived From Clavulanic Acid; 
Notice of Commission Decision Not to Review an Initial Determination 
Terminating the Investigation on the Basis of a Settlement Agreement

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission has determined not to review the presiding administrative 
law judge's (``ALJ'') initial determination (``ID'') terminating the 
above-referenced investigation in its entirety based on a settlement 
agreement.

FOR FURTHER INFORMATION CONTACT: Jean Jackson, Esq., Office of the 
General Counsel, U.S. International Trade Commission, 500 E Street, 
SW., Washington, DC 20436, telephone (202) 205-3104. Copies of the 
ALJ's ID and all other nonconfidential documents filed in connection 
with this investigation are or will be available for inspection during 
official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the 
Secretary, U.S. International Trade Commission, 500 E Street, SW., 
Washington, DC 20436, telephone (202) 205-2000. Hearing-impaired 
persons are advised that information on this matter can be obtained by 
contacting the Commission's TTD terminal on (202) 205-1810. The public 
record for this investigation may be viewed on the Commission's 
electronic docket (EDIS) at http://edis.usitc.gov. General information 
concerning the Commission may also be obtained by accessing its 
internet server (http://www.usitc.gov).

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation 
on September 5, 2002, based on a complaint filed by GlaxoSmithKline, 
PLC of the United Kingdom and SmithKlineBeecham d/b/a GlaxoSmithKline 
of Philadelphia, Pennsylvania (collectively, GSK) alleging a violation 
of section 337 of the Tariff Act of 1930 in the importation, sale for 
importation, and sale after importation of certain coamoxiclav 
products, potassium clavulanate products, and other products derived 
from clavulanic acid products and potassium clavulanate by reason of 
misappropriation of trade secrets and unfair competition. 67 FR 57850. 
The complainant named Biochemie GmbH, of Austria, Biochemie SpA, of 
Italy, Novartis AG of Switzerland, and Geneva Pharmaceuticals of New 
Jersey as respondents.
    On July 11, 2003, the ALJ issued an ID granting a joint motion by 
GSK and all respondents to the investigation to terminate the 
investigation on the basis of a settlement agreement. The motion was 
supported by the Commission investigative attorney. No petitions for 
review of the ID were filed.
    The authority for the Commission's determination is contained in 
section 337 of the Tariff Act of 190, as amended, 19 U.S.C. 1337, and 
in section 210.42(h) of the Commission's Rules of Practice and 
Procedure, 19 CFR 210.42(h).

    Issued: August 5, 2003.

    By order of the Commission.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. 03-20492 Filed 8-11-03; 8:45 am]
BILLING CODE 7020-02-P